RWE Masterclass 4: ‘Individualizing Benefit Risk’ Session 4: ‘Individualizing Benefit Risk’, will take place on Wednesday, 16 June 2021 at 5 pm CEST MORE INFORMATION|REGISTER HERE SUMMARY: Conventional methods of benefit-risk overly focus on overall results; subgroups have limitations, and the relative importance of events may not be considered. Individualizing benefit-risk more precisely would…
Read more
RWE Masterclass 3: ‘Non-randomised comparative studies’ Non-randomised comparative studies will be the main topic of the next session of our Real-World Evidence Masterclass Series. This Masterclass mini-series are meant for attendees to learn about perspectives on RWE studies with the help of two experts in this particular field: Professor Stuart Pocock, renewed trialist and statistician, and…
Read more
RWE Live Masterclass 2: ‘The Tyranny of Propensity Scores’ Propensity Scores will be the main topic of the next session of our Real-World Evidence Masterclass Series. This Masterclass mini-series are meant for attendees to learn about perspectives on RWE studies with the help of two experts in this particular field: Professor Stuart Pocock, renewed trialist…
Read more
Real-World Evidence & Trials Masterclass Series 2021 OXON Epidemiology will be hosting a Real-World Evidence Masterclass Series for all professionals interested in learning about the role of Real-World Data studies and their pros and cons compared with trials. Real-World Evidence (RWE) is a key opportunity to better understand the diseases and patient needs. Besides, all…
Read more
OXON is delighted to be supporting ICPE again this year with a virtual exhibition booth from which we will be happy to speak with you about our specialisation in data collection, secondary data and hybrid real world studies, pragmatic trials and meta-analyses to help plan, design and implement RWE for safety, market access and drug development.
OXON is delighted to be supporting ICPE again this year with a virtual exhibition booth from which we will be happy to speak with you about our specialisation in data collection, secondary data and hybrid real world studies, pragmatic trials and meta-analyses to help plan, design and implement RWE for safety, market access and drug development.
OXON Epidemiology leads a group of international European academics and clinicians to conduct the ‘RAPID COVID-19’ research programme of hospitalised COVID-19 patients.
OXON collaborates with academics and clinicians in not-for-profit international programme to evaluate non-randomised comparative studies of treatments for COVID-19 and prognostic factors
OXON will be speaking and exhibiting at World Drug Safety Congress 2019 in Amsterdam on September 10-11, 2019.
OXON will be speaking and exhibiting at World Drug Safety Congress 2019 in Amsterdam on September 10-11, 2019.
